Process For Producing Monoclonal Antibodies Reactive With Human Breast Cancer
Description of Invention:
Breast cancer is the second leading cause of cancer death among women, having only recently been surpassed by lung cancer. The incidence rate has remained somewhat steady, and is currently about 108 per 100,000. This invention describes a process to produce antibodies from hybridoma cultures for the detection, prognosis, and treatment of human breast cancer. These eleven antibodies are activated only by tumor cells from human mammary cells and not by apparently normal human tissues. The isotypes of ten of the antibodies are IgG of various subclasses, and one is IgM. The antibodies may be useful in five major areas in the management of human breast cancer: (1) the diagnosis of primary and metastatic breast tumor lesions by assay of human body fluids; (2) the in-situ detection, via gamma scanning, of primary or metastatic breast tumor lesions; (3) the treatment of primary or metastatic breast cancer using one or a combination of the antibodies either alone or coupled with toxic drugs, compounds, or radioactive isotopes; (4) use of the antibodies in the staining of populations of human cells in tissue sections from tumor lesions to indicate the degree of malignancy of the cell populations; and (5) the detection of micro-lesions containing only a few tumor cells that could not be detected by conventional staining techniques.
Inventors:
J Schlom (NCI) D Colcher (NCI) M Nuti (NCI) PM Hand (NCI) FC Austin (NCI)
Patent Status:
DHHS Reference No. E-185-1981/0 --
U.S. Patent 4,522,918 issued 11 Jun 1985
U.S. Patent 4,612,282 issued 16 Sep 1986
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-MAb Based Cancer -Diagnostics Cancer -Research Materials
For Additional Information Please Contact: Michelle A. Booden Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)451-7337
Email: boodenm@mail.nih.gov
Fax: (301) 402-0220
